The IKF-575/RENAISSANCE trial presented at ASCO 2024 explored the role of surgical intervention in limited-metastatic EGA/GEJ cancer following systemic induction therapy.17 In the study, previously untreated patients with limited metastatic disease received 4 cycles of FLOT along with trastuzumab or nivolumab if their tumors were either HER2 or PD-L1 positive, respectively. Here, ERBB2 is linked to metastatic neoplasm.